Motley Fool transcribed the earnings call.
Note: Lightly edited for style and clarity.
Five quotes from the call:
1. CEO and President Kevin Conroy on Exact’s long-term goal: “Cologuard’s momentum gives us confidence we’ll reach our long-term goal of at least 40 percent share of the U.S. colon cancer screening market.”
2. Mr. Conroy on Exact’s 2019 priorities: “The Exact Sciences team is focused on three priorities in 2019: powering our partnership with Pfizer, enhancing Cologuard and advancing our pipeline of blood-based cancer diagnostic tests.”
3. Mr. Conroy on the decision to attempt to expand Cologuard’s indication: “To expand access to Cologuard and its total market potential to nearly $18 billion, we recently submitted our application to the FDA for a label expansion to age 45. Expanding Cologuard’s FDA label to the nearly 19 million average-risk Americans between ages 45 and 49 is an important opportunity. More than 10 percent of the total years of life lost to colorectal cancer are due to a diagnosis between ages 45 and 49. This exceeds the impact and every five-year age group above age 70.”
4. Mr. Conroy on Cologuard 2.0: “We have seen data; it’s quite promising internally and our goal with Cologuard 2.0 is to maintain the same level of sensitivity for detecting cancer — 92 percent, and 90 percent stage 1 — so when you’re in a screening setting you don’t want to miss cancers, especially early-stage cancers. And then our primary goal thereafter is to improve the specificity and therefore lower the false-positive rate.”
5. On Cologuard’s resonance in the GI community: “We have 8,000 ordering doctors, but they’ve ordered very thinly in the GI community, but yet we know they influence their primary care networks. … Clearly GI are biased a colonoscopy, but they also recognize the value of a noninvasive test and they recognize the value of Cologuard as the best noninvasive test available, and now that it has universal coverage, we see that there is a real partnership opportunity here that will enable us to grow this brand, a 40 percent market share over time.”
More articles on gastroenterology:
Dr. Kellen Jex joins Riverpark Medical Center — 3 insights
Capital Digestive Care reopening office — 3 insights
6 GI-focused ASCs, endoscopy centers opened or announced in March & April
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
